The fall of the stock's price may be related to the negative forecast from JPMorgan. The bank changed the rating of Moderna from "above the market average" to "neutral" and reduced the target price of the company's shares from $89 to $60. At the same time, the bank stressed that it is still optimistic about Moderna in the long term.